Hypertension is a major health problem worldwide, yet remains under-diagnosed and under-
treated. Angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]) …

Valsartan is a nonpeptide angiotensin receptor antagonist that selectively blocks the binding
of angiotensin II to the angiotensin II type 1 receptor. The efficacy, tolerability and safety of …

In-office blood pressure (BP) measurements have recognized limitations, including the
inability to collect BP information over a long period of time, and during an individual's usual …

Angiotensin‐receptor blockers are often considered insufficiently efficacious in reducing
blood pressure. However, newer angiotensin‐receptor blockers may be more effective than …

Objectives: Angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs])
have been shown to be effective and well tolerated in hypertensive patients. Olmesartan is …

Objectives: High 24-h ambulatory blood pressure (ABP) variability is associated with poor
cardiovascular outcomes. We analysed a large ABP monitoring database containing data …

The worldwide burden of cardiovascular disease is growing. In addition to lifestyle changes,
pharmacologic agents that can modify cardiovascular disease processes have the potential …

Abstract Aims Angiotensin receptor blockers (ARBs) are available in different dosages and it
is common clinical practice to uptitrate if blood pressure goal is not achieved with the initial …

Olmesartan medoxomil is an angiotensin II receptor antagonist. In pooled analyses of seven
randomized, double-blind trials, 8 weeks' treatment with olmesartan medoxomil was …

A range of angiotensin II receptor blockers (ARB) is available, and analyses suggest there
are differences between agents in terms of antihypertensive efficacy and 24-hour blood …